Patricia G Cavero, MD
Cardiovascular Disease (Cardiology) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 38 years
- Northwestern University Feinberg Medical School, 1988
Offices
1 location · Cardiovascular Medical Group · 8 clinicians in this group
Hospitals listed: Ahmc Seton Medical Center · California Pacific Medical Center - Mission Bernal · Mills-Peninsula Medical Center · UCSF Health Hyde Hospital · UCSF Health Stanyan Hospital. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cavero’s office at (415) 933-9100 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G65848 · Current
Licensed to practise in California · since 1989 · expires 2027-05-31 · Northwestern University Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ahmc Seton Medical CenterDaly City, CAAcute Care Hospital · Proprietary · Has an emergency departmentPatients rate it 3 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsNo measure marked better or worse than the national rate
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- UCSF Health Saint Francis HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 61% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.251, Oct 2024 – Sep 2025
- UCSF Health St. Mary'S HospitalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Ahmc Seton Medical Center
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 2 the same, 0 worse of 3 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.98 (0 to 2.04) · 229 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.49 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 34 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.5 · 103 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.9 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.9 · 36 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 739 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 1,636 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.09 to 0.51) · 1,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.47 (1.02 to 5.93) · 355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 44 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.77 (1.1 to 4.43) · 361 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.62 (0 to 18.38) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.98 (1.71 to 10.25) · 43 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 73 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.3 (0 to 1.23) · 1,387 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 30 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 77 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 190 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.4 · 53 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 26.4 · 110 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 63.8 · 154 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 258 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 48 cases | No different | Jan 2022 – Dec 2024 |
What patients said (257 patients answered, 20% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 59% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for UCSF Health Saint Francis Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 0 better, 5 the same, 2 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.251 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 146 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.41 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.8 · 52 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.6 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 37 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 379 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,255 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,226 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.5 (1.04 to 5.97) · 221 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.52 to 3.89) · 222 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.17 (0 to 16.08) · 111 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.97 (0.74 to 9.21) · 87 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.2 to 3.23) · 55 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.34 (0 to 1.32) · 1,068 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 35 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.499 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 55 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 15.7 · 61 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 54 · 84 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.6 (10.1 to 18.1) · 87 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.6) · 35 cases | No different | Jan 2024 – Dec 2024 |
What patients said (217 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 68% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 62% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 61% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for UCSF Health St. Mary'S Hospital
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 413 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.96 (0.58 to 1.34) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 146.74 (92.54 to 200.93) · 30 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.4 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 51 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.3 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 102 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,363 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.02 to 0.46) · 2,530 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.12 to 0.53) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.02 (0.73 to 5.31) · 590 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.35) · 238 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (0.43 to 3.7) · 554 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 12.7 (4.19 to 21.21) · 259 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.67 (1.51 to 9.83) · 203 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 168 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.99) · 2,258 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 158 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 61 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.1 · 291 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.4 · 251 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 5.5 · 189 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 213 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.5) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12 (8.3 to 17.1) · 30 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 176 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.6 to 17.8) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 113 cases | No different | Jan 2024 – Dec 2024 |
What patients said (587 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$116,886
Medicare paid this office $116,886 for 335 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 148 | $34,478 | $105 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $11,993 | $461 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 51 | $10,000 | $189 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 135 | $8,376 | $61 |
| Short return visit (20+ min) | 85 | $7,069 | $67 |
See all 19 services
| Return visit (30+ min) | 148 | $34,478 | $105 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $11,993 | $461 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 51 | $10,000 | $189 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 135 | $8,376 | $61 |
| Short return visit (20+ min) | 85 | $7,069 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $5,811 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $5,700 | $70 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 26 | $3,669 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,558 | $105 |
| Long return visit (40+ min) | 23 | $3,392 | $147 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 150 | $2,660 | $12 |
| New patient visit (45+ min) | 11 | $1,566 | $142 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $1,448 | $52 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 25 | $1,444 | $58 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,379 | $115 |
| Injection, regadenoson, 0.1 mg | 25 | $580 | None |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 22 | $472 | $21 |
| Heart muscle strain imaging | 11 | $422 | $38 |
| Heart rhythm recording of continous external ekg over 8-15 days | 22 | $274 | $12 |
Procedures Medicare counted
| Coronary angioplasty and stenting | 1-10 | None |
| Pacemaker insertion or repair | 1-10 | None |
Who their Medicare patients are
335 Original Medicare patients in 2024. Average age 80 · 85 and older 30% · Women 52% · Also on Medicaid 46% · Health risk score 2.03. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 56% · Coronary heart disease 56% · Heart failure 45% · Chronic kidney disease 43% · Atrial fibrillation 41% · Depression 27% · COPD 23% · Stroke 23% · Dementia 20% · Cancer 16%.
The office billed $438,810, Medicare allowed $160,056 and paid $116,886; for 1,498 services of 52 kinds; $608 of it was for drugs given in the office and $116,278 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 335 | 1,498 | 80 | 2.03 | $438,810 | $116,886 |
| 2023 | 325 | 1,934 | 79 | 1.88 | $408,261 | $123,496 |
| 2022 | 399 | 2,211 | 79 | 1.82 | $478,937 | $137,147 |
| 2021 | 398 | 2,544 | 78 | 1.88 | $448,982 | $134,501 |
| 2020 | 409 | 1,899 | 79 | 1.81 | $390,888 | $114,408 |
| 2019 | 338 | 1,721 | 79 | 1.80 | $491,758 | $142,075 |
| 2018 | 396 | 2,087 | 78 | 2.19 | $730,040 | $156,553 |
| 2017 | 487 | 2,212 | 78 | 2.12 | $631,423 | $152,891 |
| 2016 | 493 | 2,228 | 78 | 2.01 | $636,360 | $156,073 |
| 2015 | 631 | 2,275 | 78 | 2.18 | $554,514 | $155,180 |
| 2014 | 901 | 2,625 | 77 | 2.02 | $535,562 | $155,954 |
| 2013 | 884 | 2,581 | 77 | 2.15 | $458,277 | $129,249 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Return visit (30+ min) | 145 | $34,483 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 62 | $13,129 | $196 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 22 | $10,274 | $467 |
| Short return visit (20+ min) | 94 | $9,116 | $74 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $7,049 | $62 |
| Long return visit (40+ min) | 38 | $6,930 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $4,666 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,091 | $157 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 171 | $3,220 | $13 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 22 | $3,105 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,591 | $108 |
| New patient visit (45+ min) | 19 | $2,348 | $124 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,765 | $118 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 12 | $1,133 | $54 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 22 | $1,109 | $50 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 16 | $424 | $24 |
| Heart rhythm recording of continous external ekg over 8-15 days | 15 | $238 | $13 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 13 | $227 | None |
2022: 18 services
| Return visit (30+ min) | 150 | $29,719 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $13,613 | $194 |
| Short return visit (20+ min) | 129 | $10,950 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $9,526 | $63 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 22 | $9,198 | $418 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 143 | $9,133 | $62 |
| Long return visit (40+ min) | 36 | $7,975 | $156 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,825 | $175 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,467 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,439 | $90 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 22 | $3,132 | $71 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 171 | $2,866 | $12 |
| New patient visit (45+ min) | 19 | $2,482 | $131 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 21 | $1,348 | $61 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 15 | $1,063 | $51 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $576 | $23 |
| Heart rhythm recording of continous external ekg over 8-15 days | 21 | $345 | $14 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 18 | $252 | None |
2021: 19 services
| Return visit (30+ min) | 152 | $28,512 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 69 | $14,610 | $203 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $14,309 | $462 |
| Short return visit (20+ min) | 146 | $13,497 | $71 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $8,683 | $63 |
| Long return visit (40+ min) | 34 | $6,600 | $165 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $6,067 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 31 | $5,631 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,366 | $168 |
| Ultrasound of both sides of head and neck blood flow | 17 | $3,234 | $190 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 190 | $3,089 | $13 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,713 | $94 |
| New patient visit (45+ min) | 19 | $2,569 | $135 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,965 | $123 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 26 | $1,608 | $62 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 13 | $1,132 | $51 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 21 | $513 | $24 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 26 | $477 | None |
| Heart rhythm recording of continous external ekg over 8-15 days | 21 | $326 | $16 |
2020: 19 services
| Return visit (30+ min) | 130 | $18,504 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 63 | $13,486 | $207 |
| Short return visit (20+ min) | 157 | $12,838 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 140 | $9,556 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $9,160 | $66 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 20 | $8,821 | $441 |
| Long return visit (40+ min) | 29 | $4,521 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,334 | $173 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 20 | $3,948 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $3,534 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 170 | $3,368 | $16 |
| New patient visit (45+ min) | 20 | $2,802 | $140 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 12 | $2,740 | $228 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 22 | $1,408 | $64 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $589 | $42 |
| External ekg recording for more than 48 hours up to 21 days | 16 | $448 | $28 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 16 | $395 | $25 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 15 | $241 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $157 | $11 |
2019: 20 services
| Return visit (30+ min) | 152 | $24,429 | $94 |
| Short return visit (20+ min) | 182 | $18,756 | $61 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 42 | $18,118 | $421 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 57 | $12,394 | $197 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 42 | $8,173 | $95 |
| Long return visit (40+ min) | 46 | $6,502 | $130 |
| Injection, regadenoson, 0.1 mg | 36 | $6,481 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $5,565 | $64 |
| Ultrasound of both sides of head and neck blood flow | 20 | $4,004 | $200 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 192 | $3,995 | $15 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,742 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 49 | $3,490 | $66 |
| New patient visit (45+ min) | 19 | $2,870 | $151 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 42 | $2,738 | $62 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 12 | $2,470 | $206 |
| New patient visit (60+ min) | 12 | $2,245 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,037 | $170 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 17 | $1,050 | $39 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 13 | $316 | $24 |
| External ekg recording for more than 48 hours up to 21 days | 13 | $308 | $24 |
2018: 22 services
| Return visit (30+ min) | 139 | $24,259 | $91 |
| Short return visit (20+ min) | 189 | $20,678 | $61 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $17,482 | $426 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 169 | $12,081 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $10,543 | $65 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 41 | $7,824 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 38 | $7,790 | $195 |
| Injection, regadenoson, 0.1 mg | 41 | $7,271 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $4,910 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,365 | $175 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 172 | $4,020 | $15 |
| Long return visit (40+ min) | 27 | $3,769 | $126 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 14 | $3,063 | $219 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 41 | $2,829 | $69 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,177 | $121 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 15 | $1,641 | $47 |
| New patient visit (45+ min) | 11 | $1,307 | $119 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 20 | $1,183 | $33 |
| Review by radiologist of arm or leg artery image | 11 | $961 | $74 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 36 | $715 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 36 | $480 | $13 |
| Evaluation of implantable heart and blood vessel monitoring system | 11 | $406 | $31 |
2017: 18 services
| Return visit (30+ min) | 143 | $25,708 | $97 |
| Short return visit (20+ min) | 221 | $24,802 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 127 | $23,517 | $64 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 210 | $12,679 | $56 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $9,559 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $9,426 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 41 | $9,187 | $219 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 188 | $4,073 | $15 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $3,278 | $117 |
| Ultrasound of both sides of head and neck blood flow | 14 | $2,926 | $209 |
| Long return visit (40+ min) | 16 | $2,426 | $135 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 17 | $2,207 | $61 |
| New patient visit (45+ min) | 14 | $1,714 | $122 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 66 | $1,376 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 25 | $1,160 | $34 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 66 | $924 | $13 |
| External ekg recording for more than 48 hours up to 21 days | 12 | $306 | $25 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 12 | $292 | $24 |
2016: 16 services
| Short return visit (20+ min) | 247 | $33,410 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 133 | $23,385 | $64 |
| Return visit (30+ min) | 95 | $14,008 | $99 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 198 | $12,388 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 47 | $11,846 | $224 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $11,184 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $11,117 | $93 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 21 | $5,230 | $227 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 179 | $3,740 | $16 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,525 | $122 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 36 | $2,452 | $35 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 15 | $2,182 | $57 |
| New patient visit (45+ min) | 12 | $1,533 | $128 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 74 | $1,478 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 74 | $976 | $13 |
| Review by radiologist of arm or leg artery image | 11 | $639 | $49 |
2015: 20 services
| Short return visit (20+ min) | 268 | $32,955 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 126 | $21,625 | $65 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 58 | $14,305 | $227 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $11,873 | $180 |
| Return visit (30+ min) | 90 | $10,844 | $95 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 139 | $8,831 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $8,195 | $93 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $3,819 | $255 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 188 | $3,688 | $15 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 15 | $3,484 | $194 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,202 | $122 |
| New patient visit (45+ min) | 15 | $2,201 | $147 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 44 | $2,175 | $33 |
| New patient visit (60+ min) | 13 | $2,002 | $154 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 193 | $1,776 | $8 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 12 | $1,559 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 60 | $1,283 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 58 | $810 | $13 |
| Programming of dual lead pacemaker system | 11 | $542 | $49 |
| Iliac and/or femoral artery angiography, non-selective, bilateral or ipsilateral to catheter insertion, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of the catheter in the distal aorta | 11 | $151 | $12 |
2014: 21 services
| Short return visit (20+ min) | 277 | $34,411 | $60 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 116 | $21,375 | $63 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 65 | $16,114 | $221 |
| New patient visit (45+ min) | 60 | $8,581 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,568 | $175 |
| Return visit (30+ min) | 70 | $7,772 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 123 | $6,999 | $56 |
| New patient visit (60+ min) | 36 | $6,650 | $185 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 20 | $5,487 | $274 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 451 | $4,246 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,608 | $90 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 194 | $3,453 | $15 |
| Ultrasound of both sides of head and neck blood flow | 18 | $3,396 | $189 |
| New patient visit (30+ min) | 33 | $2,577 | $78 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 12 | $2,563 | $214 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 35 | $1,655 | $32 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,583 | $113 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 52 | $973 | $18 |
| Programming of dual lead pacemaker system | 11 | $723 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 52 | $638 | $12 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 14 | $229 | $12 |
2013: 21 services
| Short return visit (20+ min) | 242 | $34,221 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 128 | $19,443 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 45 | $9,232 | $181 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,832 | $170 |
| New patient visit (45+ min) | 44 | $6,479 | $147 |
| Return visit (30+ min) | 55 | $6,281 | $94 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $6,275 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $5,566 | $87 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 493 | $4,255 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 155 | $3,211 | $16 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 13 | $3,008 | $231 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,256 | $119 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 29 | $1,584 | $32 |
| New patient visit (30+ min) | 13 | $1,158 | $89 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 15 | $918 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 46 | $845 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 46 | $560 | $12 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $430 | $33 |
| Electrocardiogram (ecg) 1 to 3 leads with review by physician only | 32 | $353 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 13 | $242 | $19 |
| Renal angiography, non-selective, one or both kidneys, performed at the same time as cardiac catheterization and/or coronary angiography, includes positioning or placement of any catheter in the abdominal aorta at or near the origins (ostia) of the renal a | 13 | $138 | $11 |
Medicaid work
$16,902 in 2024
Medicaid paid $16,902 for 330 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 171 | $9,734 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 50 | $5,285 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 85 | $1,168 |
| Short return visit (20+ min) | 24 | $715 |
| 2024 | 330 | 4 | 29 | $16,902 |
| 2023 | 373 | 3 | 25 | $13,107 |
| 2022 | 285 | 4 | 19 | $9,600 |
| 2021 | 248 | 4 | 16 | $7,138 |
| 2020 | 98 | 3 | 16 | $3,794 |
| 2019 | 332 | 3 | 32 | $5,785 |
| 2018 | 765 | 4 | 31 | $16,106 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 167 | $6,607 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 50 | $4,782 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 156 | $1,718 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 72 | $5,388 |
| Return visit (30+ min) | 99 | $2,712 |
| Short return visit (20+ min) | 26 | $877 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 88 | $623 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 53 | $3,978 |
| Return visit (30+ min) | 95 | $2,161 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 87 | $840 |
| Short return visit (20+ min) | 13 | $158 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 28 | $2,710 |
| Short return visit (20+ min) | 42 | $846 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 28 | $238 |
2019
| Short return visit (20+ min) | 175 | $3,515 |
| Return visit (30+ min) | 46 | $1,151 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 111 | $1,119 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 179 | $7,085 |
| Short return visit (20+ min) | 248 | $4,201 |
| Return visit (30+ min) | 152 | $3,212 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 186 | $1,608 |
Drugs they prescribed that Part D paid
$656,847
Pharmacies billed $656,847 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,348) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
2,849 generic and 499 brand-name prescriptions · $656,847 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 284 | $375,901 | $1,324 |
| Xarelto | 34 | $51,048 | $1,501 |
| Repatha Sureclick | 27 | $42,057 | $1,558 |
| Farxiga | 25 | $31,448 | $1,258 |
| Entresto | 19 | $21,118 | $1,111 |
See all 40 drugs
| Eliquis | 284 | $375,901 | $1,324 |
| Xarelto | 34 | $51,048 | $1,501 |
| Repatha Sureclick | 27 | $42,057 | $1,558 |
| Farxiga | 25 | $31,448 | $1,258 |
| Entresto | 19 | $21,118 | $1,111 |
| Brilinta | 17 | $18,923 | $1,113 |
| Nexlizet | 14 | $16,325 | $1,166 |
| Edarbi | 18 | $10,493 | $583 |
| Metoprolol | 417 | $8,375 | $20 |
| Atorvastatin | 371 | $6,648 | $18 |
| Praluent | 11 | $6,487 | $590 |
| Vascepa | 15 | $5,774 | $385 |
| Rosuvastatin | 223 | $5,627 | $25 |
| Ezetimibe | 147 | $4,124 | $28 |
| Carvedilol | 177 | $3,904 | $22 |
| Valsartan | 51 | $2,827 | $55 |
| Amlodipine Besylate | 246 | $2,186 | $9 |
| Diltiazem 24hr Er (Cd) | 40 | $2,038 | $51 |
| Losartan | 154 | $1,850 | $12 |
| Clopidogrel | 98 | $1,550 | $16 |
| Isosorbide Mononitrate Er | 65 | $1,510 | $23 |
| Spironolactone | 140 | $1,180 | $8 |
| Diltiazem | 43 | $957 | $22 |
| Lovastatin | 31 | $826 | $27 |
| Amiodarone | 25 | $749 | $30 |
| Torsemide | 23 | $712 | $31 |
| Metoprolol | 99 | $637 | $6 |
| Lisinopril | 62 | $566 | $9 |
| Furosemide | 97 | $473 | $5 |
| Hydrochlorothiazide | 44 | $408 | $9 |
| Warfarin | 37 | $389 | $11 |
| Hydralazine | 32 | $357 | $11 |
| Nebivolol | 15 | $352 | $23 |
| Digoxin | 11 | $351 | $32 |
| Benazepril | 24 | $319 | $13 |
| Atenolol | 14 | $226 | $16 |
| Simvastatin | 13 | $209 | $16 |
| Pantoprazole | 11 | $144 | $13 |
| Potassium Chloride | 11 | $134 | $12 |
| Losartan-Hydrochlorothiazide | 12 | $92 | $8 |
Year by year
| 2024 | 3,348 | 458 | 0% (0) | 15% | $656,847 |
| 2023 | 3,281 | 476 | 0% (0) | None | $631,138 |
| 2022 | 2,922 | 425 | 0% (0) | None | $533,258 |
| 2021 | 2,789 | 419 | 0% (0) | 13% | $399,540 |
| 2020 | 2,587 | 379 | 0% (0) | 13% | $312,329 |
| 2019 | 2,309 | 344 | 0% (0) | 11% | $203,688 |
| 2018 | 2,329 | 314 | 0% (0) | 10% | $193,743 |
| 2017 | 2,420 | 311 | 0% (0) | 13% | $183,127 |
| 2016 | 2,524 | 320 | 0% (0) | 14% | $173,039 |
| 2015 | 2,507 | 319 | None | 15% | $136,765 |
| 2014 | 2,757 | 325 | 0% (0) | 15% | $128,979 |
| 2013 | 2,432 | 278 | None | 15% | $103,399 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Eliquis | 303 | $379,436 | $1,252 |
| Xarelto | 43 | $56,104 | $1,305 |
| Entresto | 20 | $26,321 | $1,316 |
| Repatha Sureclick | 20 | $21,672 | $1,084 |
| Nexlizet | 13 | $15,878 | $1,221 |
| Brilinta | 12 | $14,669 | $1,222 |
| Metoprolol | 424 | $11,905 | $28 |
| Atorvastatin | 369 | $8,156 | $22 |
| Rosuvastatin | 215 | $7,429 | $35 |
| Ezetimibe | 129 | $5,268 | $41 |
| Carvedilol | 155 | $5,061 | $33 |
| Icosapent Ethyl | 12 | $4,509 | $376 |
| Amlodipine Besylate | 229 | $4,032 | $18 |
| Losartan | 164 | $3,649 | $22 |
| Valsartan | 41 | $2,675 | $65 |
| Diltiazem 24hr Er (Cd) | 50 | $2,640 | $53 |
| Isosorbide Mononitrate Er | 78 | $2,579 | $33 |
| Clopidogrel | 100 | $2,344 | $23 |
| Amiodarone | 33 | $1,694 | $51 |
| Metoprolol | 109 | $1,321 | $12 |
| Spironolactone | 103 | $1,265 | $12 |
| Torsemide | 30 | $1,151 | $38 |
| Lovastatin | 39 | $1,122 | $29 |
| Hydralazine | 47 | $904 | $19 |
| Warfarin | 37 | $887 | $24 |
| Lisinopril | 56 | $858 | $15 |
| Furosemide | 101 | $824 | $8 |
| Indapamide | 12 | $776 | $65 |
| Diltiazem | 22 | $578 | $26 |
| Hydrochlorothiazide | 59 | $517 | $9 |
| Digoxin | 12 | $389 | $32 |
| Potassium Chloride | 11 | $353 | $32 |
| Benazepril | 18 | $301 | $17 |
| Simvastatin | 13 | $258 | $20 |
2022: 32 drugs
| Eliquis | 229 | $290,374 | $1,268 |
| Xarelto | 38 | $54,838 | $1,443 |
| Entresto | 19 | $23,419 | $1,233 |
| Brilinta | 16 | $19,115 | $1,195 |
| Vascepa | 23 | $12,498 | $543 |
| Metoprolol | 361 | $11,287 | $31 |
| Atorvastatin | 347 | $7,525 | $22 |
| Rosuvastatin | 161 | $7,411 | $46 |
| Ezetimibe | 81 | $6,728 | $83 |
| Carvedilol | 154 | $3,723 | $24 |
| Amiodarone | 30 | $2,736 | $91 |
| Amlodipine Besylate | 170 | $2,493 | $15 |
| Diltiazem 24hr Er (Cd) | 50 | $2,459 | $49 |
| Losartan | 139 | $2,435 | $18 |
| Clopidogrel | 111 | $2,284 | $21 |
| Isosorbide Mononitrate Er | 85 | $2,253 | $27 |
| Torsemide | 33 | $1,645 | $50 |
| Metoprolol | 98 | $1,505 | $15 |
| Warfarin | 45 | $1,201 | $27 |
| Valsartan | 28 | $1,172 | $42 |
| Spironolactone | 71 | $1,048 | $15 |
| Lovastatin | 37 | $865 | $23 |
| Furosemide | 100 | $749 | $7 |
| Lisinopril | 50 | $700 | $14 |
| Digoxin | 22 | $624 | $28 |
| Nitroglycerin | 19 | $622 | $33 |
| Hydralazine | 32 | $589 | $18 |
| Potassium Chloride | 22 | $560 | $25 |
| Hydrochlorothiazide | 55 | $491 | $9 |
| Irbesartan | 14 | $447 | $32 |
| Simvastatin | 20 | $371 | $19 |
| Benazepril | 15 | $232 | $15 |
2021: 34 drugs
| Eliquis | 195 | $193,476 | $992 |
| Xarelto | 50 | $66,688 | $1,334 |
| Entresto | 17 | $20,870 | $1,228 |
| Metoprolol | 320 | $11,784 | $37 |
| Rosuvastatin | 164 | $6,671 | $41 |
| Atorvastatin | 307 | $6,088 | $20 |
| Carvedilol | 177 | $4,814 | $27 |
| Amiodarone | 34 | $4,283 | $126 |
| Ezetimibe | 68 | $4,198 | $62 |
| Valsartan | 21 | $2,539 | $121 |
| Losartan | 136 | $2,451 | $18 |
| Isosorbide Mononitrate Er | 82 | $2,424 | $30 |
| Diltiazem 24hr Er (Cd) | 36 | $2,380 | $66 |
| Amlodipine Besylate | 163 | $1,993 | $12 |
| Clopidogrel | 109 | $1,836 | $17 |
| Metoprolol | 98 | $1,440 | $15 |
| Torsemide | 33 | $1,177 | $36 |
| Spironolactone | 60 | $1,121 | $19 |
| Potassium Chloride | 26 | $1,119 | $43 |
| Warfarin | 49 | $1,017 | $21 |
| Hydrochlorothiazide | 73 | $835 | $11 |
| Lovastatin | 35 | $713 | $20 |
| Furosemide | 93 | $676 | $7 |
| Digoxin | 17 | $605 | $36 |
| Hydralazine | 32 | $599 | $19 |
| Losartan-Hydrochlorothiazide | 12 | $580 | $48 |
| Lisinopril | 44 | $493 | $11 |
| Prasugrel | 14 | $490 | $35 |
| Simvastatin | 39 | $447 | $11 |
| Benazepril | 24 | $319 | $13 |
| Omeprazole | 14 | $241 | $17 |
| Diltiazem | 13 | $136 | $10 |
| Atenolol | 12 | $86 | $7 |
| Sotalol | 12 | $82 | $7 |
2020: 31 drugs
| Eliquis | 158 | $160,754 | $1,017 |
| Xarelto | 42 | $51,620 | $1,229 |
| Metoprolol | 313 | $10,791 | $34 |
| Atorvastatin | 269 | $5,656 | $21 |
| Rosuvastatin | 102 | $4,790 | $47 |
| Ezetimibe | 45 | $4,002 | $89 |
| Carvedilol | 144 | $3,441 | $24 |
| Isosorbide Mononitrate Er | 88 | $2,476 | $28 |
| Diltiazem 24hr Er (Cd) | 35 | $2,409 | $69 |
| Bystolic | 14 | $2,184 | $156 |
| Amlodipine Besylate | 154 | $2,148 | $14 |
| Losartan | 153 | $2,118 | $14 |
| Clopidogrel | 112 | $2,077 | $19 |
| Metoprolol | 108 | $1,660 | $15 |
| Amiodarone | 24 | $1,428 | $59 |
| Potassium Chloride | 38 | $1,320 | $35 |
| Hydrochlorothiazide | 77 | $1,058 | $14 |
| Warfarin | 48 | $1,010 | $21 |
| Olmesartan Medoxomil | 11 | $914 | $83 |
| Lovastatin | 41 | $864 | $21 |
| Torsemide | 24 | $858 | $36 |
| Spironolactone | 58 | $854 | $15 |
| Furosemide | 110 | $823 | $7 |
| Simvastatin | 53 | $607 | $11 |
| Digoxin | 13 | $547 | $42 |
| Lisinopril | 37 | $408 | $11 |
| Hydralazine | 16 | $280 | $18 |
| Benazepril | 28 | $267 | $10 |
| Atenolol | 18 | $229 | $13 |
| Omeprazole | 21 | $164 | $8 |
| Famotidine | 13 | $56 | $4 |
2019: 30 drugs
| Eliquis | 109 | $96,545 | $886 |
| Xarelto | 18 | $22,773 | $1,265 |
| Brilinta | 15 | $10,057 | $670 |
| Metoprolol | 249 | $9,234 | $37 |
| Atorvastatin | 263 | $6,327 | $24 |
| Rosuvastatin | 73 | $3,638 | $50 |
| Carvedilol | 166 | $3,184 | $19 |
| Ezetimibe | 46 | $3,130 | $68 |
| Potassium Chloride | 43 | $2,853 | $66 |
| Isosorbide Mononitrate Er | 113 | $2,731 | $24 |
| Amlodipine Besylate | 176 | $2,327 | $13 |
| Amiodarone | 21 | $1,883 | $90 |
| Clopidogrel | 93 | $1,810 | $19 |
| Losartan | 124 | $1,555 | $13 |
| Metoprolol | 95 | $1,130 | $12 |
| Lovastatin | 44 | $958 | $22 |
| Spironolactone | 56 | $950 | $17 |
| Warfarin | 47 | $816 | $17 |
| Valsartan | 16 | $797 | $50 |
| Cartia Xt | 12 | $794 | $66 |
| Furosemide | 91 | $779 | $9 |
| Hydrochlorothiazide | 63 | $711 | $11 |
| Hydralazine | 19 | $593 | $31 |
| Simvastatin | 41 | $542 | $13 |
| Metolazone | 13 | $432 | $33 |
| Nitroglycerin | 21 | $425 | $20 |
| Lisinopril | 28 | $372 | $13 |
| Benazepril | 33 | $322 | $10 |
| Atenolol | 15 | $238 | $16 |
| Omeprazole | 11 | $142 | $13 |
2018: 32 drugs
| Eliquis | 91 | $70,897 | $779 |
| Xarelto | 19 | $22,777 | $1,199 |
| Atorvastatin | 270 | $8,964 | $33 |
| Metoprolol | 175 | $7,541 | $43 |
| Carvedilol | 182 | $6,032 | $33 |
| Isosorbide Mononitrate Er | 108 | $3,945 | $37 |
| Potassium Chloride | 58 | $3,744 | $65 |
| Ezetimibe | 26 | $3,075 | $118 |
| Amlodipine Besylate | 181 | $3,055 | $17 |
| Clopidogrel | 82 | $2,821 | $34 |
| Lovastatin | 56 | $2,178 | $39 |
| Losartan | 135 | $1,831 | $14 |
| Amiodarone | 37 | $1,775 | $48 |
| Rosuvastatin | 50 | $1,760 | $35 |
| Propafenone | 14 | $1,185 | $85 |
| Warfarin | 51 | $1,067 | $21 |
| Spironolactone | 78 | $1,043 | $13 |
| Cartia Xt | 18 | $944 | $52 |
| Digoxin | 12 | $866 | $72 |
| Metoprolol | 102 | $808 | $8 |
| Furosemide | 95 | $698 | $7 |
| Nitroglycerin | 26 | $598 | $23 |
| Simvastatin | 28 | $559 | $20 |
| Valsartan | 18 | $546 | $30 |
| Hydralazine | 26 | $530 | $20 |
| Hydrochlorothiazide | 55 | $448 | $8 |
| Benazepril | 39 | $389 | $10 |
| Lisinopril | 37 | $368 | $10 |
| Tamsulosin | 12 | $360 | $30 |
| Ramipril | 13 | $223 | $17 |
| Atenolol | 14 | $174 | $12 |
| Jantoven | 12 | $110 | $9 |
2017: 33 drugs
| Eliquis | 60 | $43,176 | $720 |
| Xarelto | 24 | $23,579 | $982 |
| Atorvastatin | 252 | $8,736 | $35 |
| Metoprolol | 165 | $6,191 | $38 |
| Ezetimibe | 17 | $6,182 | $364 |
| Carvedilol | 195 | $4,830 | $25 |
| Isosorbide Mononitrate Er | 120 | $4,034 | $34 |
| Potassium Chloride | 62 | $3,622 | $58 |
| Clopidogrel | 94 | $3,319 | $35 |
| Amlodipine Besylate | 180 | $2,615 | $15 |
| Lovastatin | 77 | $2,464 | $32 |
| Losartan | 143 | $2,077 | $15 |
| Amiodarone | 21 | $1,610 | $77 |
| Rosuvastatin | 48 | $1,590 | $33 |
| Warfarin | 78 | $1,452 | $19 |
| Digoxin | 13 | $1,066 | $82 |
| Metoprolol | 108 | $1,037 | $10 |
| Pravastatin | 22 | $966 | $44 |
| Spironolactone | 77 | $816 | $11 |
| Furosemide | 139 | $808 | $6 |
| Cartia Xt | 19 | $784 | $41 |
| Valsartan | 18 | $596 | $33 |
| Simvastatin | 30 | $560 | $19 |
| Benazepril | 46 | $481 | $10 |
| Hydralazine | 22 | $465 | $21 |
| Lisinopril | 39 | $418 | $11 |
| Metolazone | 18 | $396 | $22 |
| Nitroglycerin | 20 | $371 | $19 |
| Ramipril | 14 | $344 | $25 |
| Hydrochlorothiazide | 35 | $296 | $8 |
| Omeprazole | 13 | $167 | $13 |
| Atenolol | 17 | $162 | $10 |
| Pantoprazole | 11 | $116 | $11 |
2016: 37 drugs
| Eliquis | 51 | $34,061 | $668 |
| Xarelto | 28 | $18,673 | $667 |
| Zetia | 18 | $14,593 | $811 |
| Bystolic | 20 | $7,696 | $385 |
| Metoprolol | 170 | $7,535 | $44 |
| Atorvastatin | 173 | $4,893 | $28 |
| Amiodarone | 31 | $4,454 | $144 |
| Advair Diskus | 12 | $4,151 | $346 |
| Isosorbide Mononitrate Er | 135 | $3,880 | $29 |
| Carvedilol | 222 | $2,813 | $13 |
| Potassium Chloride | 51 | $2,618 | $51 |
| Clopidogrel | 111 | $1,989 | $18 |
| Warfarin | 95 | $1,965 | $21 |
| Digoxin | 30 | $1,915 | $64 |
| Lovastatin | 89 | $1,694 | $19 |
| Pravastatin | 30 | $1,666 | $56 |
| Losartan | 124 | $1,396 | $11 |
| Valsartan | 24 | $1,380 | $57 |
| Metoprolol | 134 | $1,132 | $8 |
| Amlodipine Besylate | 173 | $1,096 | $6 |
| Valsartan-Hydrochlorothiazide | 16 | $1,082 | $68 |
| Spironolactone | 95 | $1,077 | $11 |
| Rosuvastatin | 19 | $991 | $52 |
| Cartia Xt | 15 | $752 | $50 |
| Hydralazine | 18 | $686 | $38 |
| Furosemide | 128 | $660 | $5 |
| Lisinopril | 45 | $615 | $14 |
| Nifedipine Er | 15 | $579 | $39 |
| Nitrostat | 20 | $542 | $27 |
| Benazepril | 50 | $489 | $10 |
| Ramipril | 17 | $440 | $26 |
| Simvastatin | 41 | $417 | $10 |
| Hydrochlorothiazide | 24 | $323 | $13 |
| Pantoprazole | 17 | $199 | $12 |
| Allopurinol | 11 | $193 | $18 |
| Atenolol | 22 | $147 | $7 |
| Famotidine | 12 | $78 | $6 |
2015: 34 drugs
| Xarelto | 26 | $18,513 | $712 |
| Bystolic | 34 | $9,237 | $272 |
| Metoprolol | 159 | $7,554 | $48 |
| Amiodarone | 45 | $6,479 | $144 |
| Valsartan | 27 | $3,735 | $138 |
| Atorvastatin | 129 | $3,313 | $26 |
| Isosorbide Mononitrate Er | 97 | $3,022 | $31 |
| Potassium Chloride | 63 | $2,955 | $47 |
| Carvedilol | 206 | $2,381 | $12 |
| Warfarin | 120 | $2,341 | $20 |
| Pravastatin | 35 | $2,071 | $59 |
| Clopidogrel | 106 | $1,903 | $18 |
| Digoxin | 38 | $1,896 | $50 |
| Lovastatin | 106 | $1,628 | $15 |
| Losartan | 117 | $1,506 | $13 |
| Amlodipine Besylate | 187 | $1,317 | $7 |
| Digox | 15 | $1,179 | $79 |
| Valsartan-Hydrochlorothiazide | 17 | $1,000 | $59 |
| Metoprolol | 140 | $960 | $7 |
| Cartia Xt | 25 | $938 | $38 |
| Nifedipine Er | 14 | $896 | $64 |
| Spironolactone | 80 | $824 | $10 |
| Benazepril | 28 | $773 | $28 |
| Diltiazem 24hr Cd | 15 | $740 | $49 |
| Hydralazine | 18 | $714 | $40 |
| Diltiazem 24hr Er | 16 | $613 | $38 |
| Nitrostat | 31 | $486 | $16 |
| Simvastatin | 63 | $483 | $8 |
| Lisinopril | 43 | $446 | $10 |
| Furosemide | 109 | $435 | $4 |
| Losartan-Hydrochlorothiazide | 17 | $434 | $26 |
| Hydrochlorothiazide | 36 | $406 | $11 |
| Atenolol | 36 | $163 | $5 |
| Clonidine | 24 | $148 | $6 |
2014: 42 drugs
| Xarelto | 26 | $13,957 | $537 |
| Metoprolol | 193 | $8,582 | $44 |
| Diovan | 17 | $7,832 | $461 |
| Clopidogrel | 105 | $6,037 | $57 |
| Valsartan | 11 | $4,208 | $383 |
| Isosorbide Mononitrate Er | 141 | $3,972 | $28 |
| Bystolic | 13 | $3,321 | $255 |
| Lovastatin | 142 | $3,203 | $23 |
| Amiodarone | 32 | $3,122 | $98 |
| Carvedilol | 204 | $2,986 | $15 |
| Losartan | 146 | $2,984 | $20 |
| Atorvastatin | 113 | $2,812 | $25 |
| Pravastatin | 63 | $2,509 | $40 |
| Warfarin | 120 | $2,445 | $20 |
| Ranexa | 12 | $2,398 | $200 |
| Amlodipine Besylate | 238 | $2,366 | $10 |
| Valsartan-Hydrochlorothiazide | 21 | $1,606 | $76 |
| Potassium Chloride | 37 | $1,403 | $38 |
| Digox | 21 | $1,379 | $66 |
| Felodipine Er | 22 | $1,285 | $58 |
| Diltiazem 24hr Er | 26 | $1,165 | $45 |
| Hydralazine | 37 | $1,045 | $28 |
| Metoprolol | 153 | $1,017 | $7 |
| Diltiazem 24hr Cd | 16 | $780 | $49 |
| Benazepril | 37 | $776 | $21 |
| Propafenone | 12 | $753 | $63 |
| Digoxin | 27 | $709 | $26 |
| Spironolactone | 60 | $682 | $11 |
| Ramipril | 13 | $665 | $51 |
| Lisinopril | 60 | $657 | $11 |
| Simvastatin | 53 | $644 | $12 |
| Furosemide | 106 | $563 | $5 |
| Losartan-Hydrochlorothiazide | 12 | $492 | $41 |
| Cartia Xt | 11 | $488 | $44 |
| Nifedipine Er | 11 | $455 | $41 |
| Pantoprazole | 19 | $428 | $23 |
| Nitrostat | 32 | $414 | $13 |
| Hydrochlorothiazide | 48 | $371 | $8 |
| Klor-Con 10 | 13 | $281 | $22 |
| Atenolol | 49 | $271 | $6 |
| Lisinopril-Hydrochlorothiazide | 11 | $238 | $22 |
| Clonidine | 21 | $108 | $5 |
2013: 39 drugs
| Diovan | 27 | $9,158 | $339 |
| Metoprolol | 171 | $7,693 | $45 |
| Zetia | 14 | $6,176 | $441 |
| Isosorbide Mononitrate Er | 142 | $3,933 | $28 |
| Clonidine | 11 | $3,641 | $331 |
| Valsartan-Hydrochlorothiazide | 26 | $3,571 | $137 |
| Niaspan | 12 | $3,425 | $285 |
| Aciphex | 11 | $3,167 | $288 |
| Clopidogrel | 79 | $3,021 | $38 |
| Lovastatin | 158 | $3,011 | $19 |
| Atorvastatin | 87 | $2,765 | $32 |
| Carvedilol | 130 | $2,616 | $20 |
| Amlodipine Besylate | 208 | $2,407 | $12 |
| Losartan | 121 | $2,274 | $19 |
| Potassium Chloride | 58 | $2,011 | $35 |
| Bystolic | 14 | $1,955 | $140 |
| Warfarin | 111 | $1,834 | $17 |
| Diltiazem 24hr Er | 32 | $1,514 | $47 |
| Metoprolol | 152 | $1,332 | $9 |
| Pravastatin | 52 | $1,255 | $24 |
| Felodipine Er | 20 | $1,109 | $55 |
| Amiodarone | 29 | $1,094 | $38 |
| Hydralazine | 32 | $1,010 | $32 |
| Ramipril | 12 | $977 | $81 |
| Propafenone | 14 | $934 | $67 |
| Cartia Xt | 26 | $770 | $30 |
| Lisinopril | 77 | $762 | $10 |
| Benazepril | 32 | $671 | $21 |
| Spironolactone | 47 | $584 | $12 |
| Furosemide | 90 | $547 | $6 |
| Digox | 35 | $481 | $14 |
| Simvastatin | 29 | $367 | $13 |
| Hydrochlorothiazide | 41 | $362 | $9 |
| Losartan-Hydrochlorothiazide | 19 | $359 | $19 |
| Propranolol | 12 | $352 | $29 |
| Nifedipine Er | 11 | $326 | $30 |
| Atenolol | 34 | $245 | $7 |
| Nitrostat | 19 | $221 | $12 |
| Clonidine | 22 | $171 | $8 |
Money from drug and device companies
$5,352 in 2025
| 2025 | 27 | 192 | None | $5,352 |
| 2024 | 26 | 192 | None | $4,747 |
| 2023 | 26 | 187 | $1,800 | $6,051 |
| 2022 | 28 | 186 | None | $4,313 |
| 2021 | 26 | 118 | None | $2,953 |
| 2020 | 22 | 87 | None | $1,857 |
| 2019 | 19 | 107 | None | $2,460 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Repatha | $518 | 21 payments
|
| AstraZeneca Pharmaceuticals LP | Wainua | $503 | 14 payments
|
| Pfizer | Eliquis | $434 | 17 payments
|
| Novo Nordisk | Wegovy | $416 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $411 | 16 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $292 | 11 payments
|
See all 192 published payments
| Novo Nordisk | Meals · 2025-12-20 | Wegovy | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-17 | Camzyos | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-17 | Camzyos | $4 |
| Esperion Therapeutics | Meals · 2025-12-17 | Nexletol | $8 |
| Esperion Therapeutics | Meals · 2025-12-17 | Nexletol | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-16 | Jardiance | $27 |
| Amgen | Meals · 2025-12-16 | Repatha | $28 |
| AGEPHA Pharma FZ | Meals · 2025-12-15 | Lodoco | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-11 | Farxiga | $24 |
| Pfizer | Meals · 2025-12-11 | Vyndaqel | $11 |
| Scpharmaceuticals | Meals · 2025-12-10 | Furoscix | $32 |
| Pfizer | Meals · 2025-12-10 | Vyndaqel | $27 |
| Scpharmaceuticals | Meals · 2025-12-09 | Furoscix | $27 |
| Amgen | Meals · 2025-12-05 | Repatha | $27 |
| Pfizer | Meals · 2025-12-05 | Eliquis | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-02 | Camzyos | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-01 | Camzyos | $27 |
| BridgeBio Pharma | Meals · 2025-11-25 | Attruby | $17 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-24 | Jardiance | $20 |
| Pfizer | Meals · 2025-11-22 | Vyndaqel | $25 |
| Baxter Healthcare | Meals · 2025-11-20 | Hillrom - Carnation Ambulatory Monitor | $9 |
| Scpharmaceuticals | Meals · 2025-11-19 | Furoscix | $30 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-18 | Kerendia | $24 |
| Pfizer | Meals · 2025-11-18 | Eliquis | $28 |
| Amgen | Meals · 2025-11-17 | Repatha | $21 |
| Novo Nordisk | Meals · 2025-11-14 | Wegovy | $13 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Leqvio | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-12 | Wainua | $28 |
| Pfizer | Meals · 2025-11-12 | Vyndaqel | $11 |
| Esperion Therapeutics | Meals · 2025-11-11 | Nexletol | $26 |
| Cleerly | Meals · 2025-11-03 | Cleerly Ischemia | $28 |
| Heartflow | Meals · 2025-10-28 | Ffrct | $168 |
| Esperion Therapeutics | Meals · 2025-10-28 | Nexletol | $5 |
| Alnylam Pharmaceuticals | Meals · 2025-10-27 | Amvuttra | $29 |
| Scpharmaceuticals | Meals · 2025-10-24 | Furoscix | $33 |
| Baxter Healthcare | Meals · 2025-10-23 | Hillrom - Carnation Ambulatory Monitor | $23 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-21 | Camzyos | $23 |
| Pfizer | Meals · 2025-10-21 | Eliquis | $31 |
| Amgen | Meals · 2025-10-20 | Repatha | $21 |
| Novo Nordisk | Meals · 2025-10-16 | Wegovy | $11 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-16 | Kerendia | $34 |
| Amgen | Meals · 2025-10-16 | Repatha | $22 |
| AGEPHA Pharma FZ | Meals · 2025-10-15 | Lodoco | $19 |
| Baxter Healthcare | Meals · 2025-10-15 | Hillrom - Cardiac Ambulatory Monitor | $12 |
| Merck Sharp & Dohme | Meals · 2025-10-14 | Capvaxive | $26 |
| BridgeBio Pharma | Meals · 2025-10-11 | Attruby | $21 |
| Novartis Pharmaceuticals | Meals · 2025-10-09 | Leqvio | $24 |
| Pfizer | Meals · 2025-10-08 | Vyndaqel | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-07 | Camzyos | $7 |
| Esperion Therapeutics | Meals · 2025-10-07 | Nexletol | $24 |
| Amgen | Meals · 2025-10-01 | Repatha | $24 |
| Amgen | Meals · 2025-09-29 | Repatha | $25 |
| Scpharmaceuticals | Meals · 2025-09-25 | Furoscix | $35 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-23 | Jardiance | $18 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-22 | Kerendia | $18 |
| Pfizer | Meals · 2025-09-20 | Eliquis | $27 |
| Amgen | Meals · 2025-09-18 | Repatha | $25 |
| Esperion Therapeutics | Meals · 2025-09-18 | Nexletol | $24 |
| Merck Sharp & Dohme | Meals · 2025-09-17 | Verquvo | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-13 | Lokelma | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-11 | Wainua | $28 |
| Lilly USA | Meals · 2025-09-10 | Mounjaro | $23 |
| Merck Sharp & Dohme | Meals · 2025-09-09 | Verquvo | $25 |
| Baxter Healthcare | Meals · 2025-09-08 | Hillrom - Carnation Ambulatory Monitor | $13 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-08 | Eliquis | $28 |
| Lilly USA | Meals · 2025-09-04 | Zepbound | $27 |
| Amgen | Meals · 2025-09-03 | Repatha | $28 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-29 | Lifevest | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-28 | Farxiga | $27 |
| Merck Sharp & Dohme | Meals · 2025-08-28 | Verquvo | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-26 | Kerendia | $31 |
| Novartis Pharmaceuticals | Meals · 2025-08-21 | Leqvio | $24 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-08-20 | Lifevest | $20 |
| Amgen | Meals · 2025-08-18 | Repatha | $25 |
| Amgen | Meals · 2025-08-13 | Repatha | $27 |
| Baxter Healthcare | Meals · 2025-08-11 | Hillrom - Carnation Ambulatory Monitor | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-08 | Kerendia | $19 |
| Novo Nordisk | Meals · 2025-08-07 | Wegovy | $104 |
| Pfizer | Meals · 2025-08-06 | Eliquis | $34 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-04 | Camzyos | $9 |
| Pfizer | Meals · 2025-08-04 | Eliquis | $21 |
| Edwards Lifesciences | Meals · 2025-08-01 | Sapien 3 Ultra Resilia | $32 |
| Alnylam Pharmaceuticals | Meals · 2025-07-31 | Amvuttra | $31 |
| Baxter Healthcare | Meals · 2025-07-30 | Hillrom - Carnation Ambulatory Monitor | $21 |
| Novartis Pharmaceuticals | Meals · 2025-07-23 | Leqvio | $34 |
| Edwards Lifesciences | Meals · 2025-07-22 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $37 |
| Pfizer | Meals · 2025-07-22 | Eliquis | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-21 | Lokelma | $87 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-17 | Jardiance | $24 |
| Lilly USA | Meals · 2025-07-15 | Zepbound | $23 |
| Esperion Therapeutics | Meals · 2025-07-15 | Nexletol | $26 |
| Amgen | Meals · 2025-07-10 | Repatha | $28 |
| BridgeBio Pharma | Meals · 2025-07-09 | Attruby | $24 |
| Abbott Laboratories | Meals · 2025-07-08 | Triclip | $23 |
| Esperion Therapeutics | Meals · 2025-07-08 | Nexletol | $26 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-07 | Camzyos | $20 |
| Alnylam Pharmaceuticals | Meals · 2025-07-02 | Amvuttra | $30 |
| Scpharmaceuticals | Meals · 2025-06-30 | Furoscix | $24 |
| Merck Sharp & Dohme | Meals · 2025-06-30 | Verquvo | $20 |
| Baxter Healthcare | Meals · 2025-06-28 | Hillrom - Carnation Ambulatory Monitor | $10 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-27 | Kerendia | $25 |
| Boston Scientific | Meals · 2025-06-25 | Watchman Flx | $27 |
| Endotronix | Meals · 2025-06-19 | Cordella Pulomonary Artery Pressure Sensor | $38 |
| Merck Sharp & Dohme | Meals · 2025-06-18 | Verquvo | $30 |
| Novo Nordisk | Meals · 2025-06-16 | Wegovy | $19 |
| Abbott Laboratories | Meals · 2025-06-13 | Jot Dx | $11 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-06-12 | Lifevest | $41 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-06-12 | Eliquis | $30 |
| Boston Scientific | Meals · 2025-06-11 | Watchman Flx | $18 |
| Novo Nordisk | Meals · 2025-06-10 | Wegovy | $17 |
| Pfizer | Meals · 2025-06-10 | Eliquis | $29 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-09 | Jardiance | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-05 | Wainua | $125 |
| Merck Sharp & Dohme | Meals · 2025-06-05 | Verquvo | $26 |
| Edwards Lifesciences | Meals · 2025-06-04 | Pascal | $21 |
| Amgen | Meals · 2025-06-04 | Repatha | $23 |
| Abbott Laboratories | Meals · 2025-06-04 | Cardiomems | $11 |
| Esperion Therapeutics | Meals · 2025-06-02 | Nexletol | $24 |
| Boston Scientific | Meals · 2025-05-29 | Imager II | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-29 | Lokelma | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-05-29 | Kerendia | $30 |
| Amgen | Meals · 2025-05-27 | Repatha | $28 |
| Scpharmaceuticals | Meals · 2025-05-22 | Furoscix | $21 |
| Pfizer | Meals · 2025-05-21 | Vyndaqel | $24 |
| Amgen | Meals · 2025-05-16 | Repatha | $26 |
| Lilly USA | Meals · 2025-05-14 | Mounjaro | $27 |
| Heartflow | Meals · 2025-05-14 | Ffrct | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-13 | Wainua | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-12 | Jardiance | $25 |
| Novo Nordisk | Meals · 2025-05-08 | Wegovy | $25 |
| Scpharmaceuticals | Meals · 2025-05-05 | Furoscix | $26 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-05-01 | Lifevest | $39 |
| Novo Nordisk | Meals · 2025-04-30 | Wegovy | $11 |
| Abbott Laboratories | Meals · 2025-04-29 | Ionicrf | $82 |
| Tactile Systems Technology | Meals · 2025-04-22 | Flexitouch Plus | $24 |
| Amgen | Meals · 2025-04-22 | Repatha | $26 |
| Alnylam Pharmaceuticals | Meals · 2025-04-21 | Amvuttra | $23 |
| Edwards Lifesciences | Meals · 2025-04-19 | Pascal | $52 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-16 | Camzyos | $20 |
| Novo Nordisk | Meals · 2025-04-15 | Wegovy | $11 |
| Novartis Pharmaceuticals | Meals · 2025-04-14 | Leqvio | $28 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-14 | Kerendia | $21 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-12 | Kerendia | $29 |
| Amgen | Meals · 2025-04-10 | Repatha | $24 |
| Novo Nordisk | Meals · 2025-04-08 | Wegovy | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-08 | Wainua | $19 |
| Pfizer | Meals · 2025-04-04 | Vyndaqel | $25 |
| Esperion Therapeutics | Meals · 2025-04-02 | Nexletol | $16 |
| Merck Sharp & Dohme | Meals · 2025-03-31 | Verquvo | $20 |
| Baxter Healthcare | Meals · 2025-03-28 | Hillrom - Carnation Ambulatory Monitor | $22 |
| Novartis Pharmaceuticals | Meals · 2025-03-27 | Leqvio | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-26 | Eliquis | $38 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-24 | Camzyos | $29 |
| Novo Nordisk | Meals · 2025-03-21 | Wegovy | $121 |
| Amgen | Meals · 2025-03-18 | Repatha | $15 |
| Abbott Laboratories | Meals · 2025-03-17 | Assurity | $10 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-13 | Kerendia | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-03-10 | Jardiance | $26 |
| Novo Nordisk | Meals · 2025-03-08 | Rybelsus | $19 |
| Edwards Lifesciences | Meals · 2025-03-05 | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $1 |
| Edwards Lifesciences | Meals · 2025-03-04 | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $35 |
| Amgen | Meals · 2025-03-04 | Repatha | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-01 | Farxiga | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-25 | Wainua | $25 |
| Esperion Therapeutics | Meals · 2025-02-23 | Nexletol | $24 |
| Boston Scientific | Meals · 2025-02-22 | General - Therapies | $85 |
| Boston Scientific | Meals · 2025-02-20 | Watchman Flx | $20 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-19 | Jardiance | $27 |
| Novo Nordisk | Meals · 2025-02-15 | Ozempic | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-13 | Camzyos | $1 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-13 | Camzyos | $27 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-12 | None | $118 |
| Novartis Pharmaceuticals | Meals · 2025-02-12 | Leqvio | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-12 | Kerendia | $29 |
| Actelion Pharmaceuticals US | Meals · 2025-02-11 | Uptravi | $41 |
| Merck Sharp & Dohme | Meals · 2025-02-10 | Verquvo | $17 |
| Baxter Healthcare | Meals · 2025-02-04 | Hillrom - Carnation Ambulatory Monitor | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-04 | Farxiga | $19 |
| Amgen | Meals · 2025-02-03 | Repatha | $24 |
| Pfizer | Meals · 2025-01-30 | Vyndaqel | $29 |
| Boston Scientific | Meals · 2025-01-28 | Watchman Flx | $24 |
| Philips North America | Meals · 2025-01-24 | Mcot | $30 |
| Lilly USA | Meals · 2025-01-23 | Mounjaro | $24 |
| Philips North America | Meals · 2025-01-16 | Mcot | $61 |
| Amgen | Meals · 2025-01-15 | Repatha | $25 |
| Medtronic | Meals · 2025-01-14 | Endurant Iis | $68 |
| Pfizer | Meals · 2025-01-09 | Eliquis | $39 |
| Philips North America | Meals · 2025-01-08 | Mcot | $34 |
| Heartflow | Meals · 2025-01-08 | Ffrct | $25 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-01-07 | Lifevest | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-07 | Farxiga | $24 |
| Boston Scientific | Meals · 2025-01-04 | Watchman Flx | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,747
| Novo Nordisk | Ozempic | $443 | 19 payments
|
| Boston Scientific | Watchman Flx | $442 | 10 payments
|
| Amgen | Repatha | $396 | 17 payments
|
| Novartis Pharmaceuticals | Entresto | $315 | 13 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $274 | 13 payments
|
| Janssen Pharmaceuticals | Xarelto | $270 | 18 payments
|
| Inari Medical | Flowtriever Catheter, S | $267 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $263 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $245 | 14 payments
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $233 | 6 payments
|
| Pfizer | Eliquis | $219 | 10 payments
|
| Merck Sharp & Dohme | Verquvo | $185 | 8 payments
|
| Abbott Laboratories | Gallant | $172 | 5 payments
|
| Esperion Therapeutics | Nexletol | $151 | 7 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $150 | 7 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $137 | 5 payments
|
| Actelion Pharmaceuticals US | Opsumit | $135 | 4 payments
|
| iRhythm Technologies | Zio Xt Patch | $110 | 6 payments
|
| Edwards Lifesciences | Sapien 3 Ultra Resilia | $75 | 3 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $68 | 3 payments
|
| Lexicon Pharmaceuticals | None | $48 | 2 payments
|
| Philips North America | (5044) Mcot | $45 | 1 payment
|
| Becton Dickinson and | Venclose Maven Catheter | $38 | 1 payment
|
| Heartflow | Ffrct | $31 | 1 payment
|
| Medtronic | Corevalve Evolut R | $21 | 1 payment
|
| Chiesi USA | Cleviprex | $16 | 1 payment
|
2023: $6,051
| Caption Health | Caption Interpretation Autoef | $1,800 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $459 | 19 payments
|
| E.R. Squibb & Sons L.L.C. | Camzyos | $446 | 16 payments
|
| Janssen Pharmaceuticals | Xarelto | $405 | 24 payments
|
| Esperion Therapeutics | Nexletol | $358 | 12 payments
|
| Amgen | Repatha | $288 | 12 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $263 | 12 payments
|
| Boston Scientific | Watchman Flx | $240 | 5 payments
|
| Novo Nordisk | Rybelsus | $229 | 12 payments
|
| Lexicon Pharmaceuticals | Inpefa | $218 | 11 payments
|
| Pfizer | Vyndaqel | $164 | 12 payments
|
| Merck Sharp & Dohme | Verquvo | $160 | 7 payments
|
| Abbott Laboratories | Cardiomems | $139 | 4 payments
|
| iRhythm Technologies | Zio Xt Patch | $134 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $105 | 5 payments
|
| Scpharmaceuticals | Furoscix | $84 | 3 payments
|
| Chiesi USA | Cleviprex | $83 | 4 payments
|
| Impulse Dynamics (USA) | Optimizer | $72 | 3 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $71 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $66 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Adempas | $66 | 2 payments
|
| Baxter Healthcare | Hillrom - Cardiac Ambulatory Monitor | $65 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $46 | 2 payments
|
| ShockWave Medical | Shockwave Ivl System With the Shockwave C2 Coronary Ivl Catheter | $41 | 1 payment
|
| Biotronik | Biomonitor | $27 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $22 | 1 payment
|
2022: $4,313
| Novo Nordisk | Ozempic | $397 | 18 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $342 | 16 payments
|
| Amgen | Repatha | $326 | 14 payments
|
| Novartis Pharmaceuticals | Entresto | $309 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $255 | 15 payments
|
| Merck Sharp & Dohme | Verquvo | $221 | 11 payments
|
| Pfizer | Vyndaqel | $208 | 13 payments
|
| Boston Scientific | General - Therapies | $204 | 4 payments
|
| Esperion Therapeutics | Nexletol | $197 | 10 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $191 | 7 payments
|
| Sanofi-Aventis U.S. | Multaq | $187 | 8 payments
|
| Cardiovascular Systems | Diamondback Coronary | $164 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $164 | 6 payments
|
| iRhythm Technologies | Zio Xt Patch | $154 | 8 payments
|
| Abbott Laboratories | Confirm Rx | $135 | 6 payments
|
| Chiesi USA | Kengreal | $133 | 7 payments
|
| Abiomed | Impella | $122 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $114 | 6 payments
|
| Bayer HealthCare Pharmaceuticals | Verquvo | $95 | 4 payments
|
| Kowa Pharmaceuticals America | Livalo | $90 | 3 payments
|
| Kiniksa Pharmaceuticals | Arcalyst | $83 | 3 payments
|
| HeartFlow | Ffrct | $51 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $39 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $39 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $37 | 1 payment
|
| Arbor Pharmaceuticals | Edarbi | $23 | 1 payment
|
| CathWorks | Ffrangio | $16 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $16 | 1 payment
|
2021: $2,953
| Esperion Therapeutics | Nexletol | $326 | 8 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $300 | 10 payments
|
| Novartis Pharmaceuticals | Entresto | $281 | 14 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $236 | 8 payments
|
| Amarin Pharma | Vascepa | $225 | 10 payments
|
| Astellas Pharma US | Lexiscan | $190 | 3 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $175 | 6 payments
|
| Sanofi-Aventis U.S. | Multaq | $154 | 7 payments
|
| Novo Nordisk | Ozempic | $147 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $107 | 5 payments
|
| Janssen Pharmaceuticals | Xarelto | $104 | 5 payments
|
| Amgen | Corlanor | $90 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Verquvo | $80 | 4 payments
|
| Kiniksa Pharmaceuticals | None | $72 | 3 payments
|
| Boston Scientific | Watchman | $67 | 3 payments
|
| Kowa Pharmaceuticals America | Livalo | $65 | 2 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $53 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $53 | 3 payments
|
| Actelion Pharmaceuticals US | Opsumit | $46 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $43 | 2 payments
|
| Arbor Pharmaceuticals | Edarbi | $39 | 2 payments
|
| Pfizer | Eliquis | $21 | 1 payment
|
| Medtronic | Reveal Linq | $20 | 1 payment
|
| Lundbeck | Northera | $20 | 1 payment
|
| Abbott Laboratories | Confirm Rx | $19 | 1 payment
|
| HeartFlow | Ffrct | $18 | 1 payment
|
2020: $1,857
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $226 | 12 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $226 | 10 payments
|
| Novartis Pharmaceuticals | Entresto | $200 | 10 payments
|
| Amarin Pharma | Vascepa | $174 | 3 payments
|
| Amgen | Corlanor | $127 | 8 payments
|
| Pfizer | Eliquis | $118 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $115 | 7 payments
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $93 | 5 payments
|
| Medtronic Vascular | Telescope | $83 | 4 payments
|
| Boston Scientific | Watchman | $70 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $68 | 4 payments
|
| Lundbeck | Northera | $67 | 3 payments
|
| CathWorks | Ffrangio System | $53 | 2 payments
|
| Astellas Pharma US | Lexiscan | $48 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $41 | 2 payments
|
| Esperion Therapeutics | Nexletol | $29 | 1 payment
|
| Abbott Laboratories | Heartmate 3 Left Ventricular Dev | $24 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $23 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $19 | 1 payment
|
| Actelion Pharmaceuticals US | Opsumit | $19 | 2 payments
|
| iRhythm Technologies | Zio Patch | $14 | 1 payment
|
2019: $2,460
| Novartis Pharmaceuticals | Entresto | $367 | 14 payments
|
| Amgen | Repatha | $308 | 13 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $283 | 9 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $277 | 15 payments
|
| Janssen Pharmaceuticals | Xarelto | $239 | 15 payments
|
| Boston Scientific | Opticross | $186 | 14 payments
|
| Sanofi-Aventis U.S. | Praluent | $152 | 3 payments
|
| Cardiovascular Systems | Coronary Orbital Atherectomy System | $129 | 2 payments
|
| United Therapeutics | None | $112 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $80 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $62 | 3 payments
|
| Osprey Medical | Dyevert | $62 | 2 payments
|
| Medtronic Vascular | Resolute | $49 | 3 payments
|
| Regeneron Healthcare Solutions | Praluent | $42 | 2 payments
|
| Actelion Pharmaceuticals US | Opsumit | $35 | 3 payments
|
| Avinger | Pantheris | $25 | 1 payment
|
| Daiichi Sankyo | Injectafer | $22 | 1 payment
|
| HeartFlow | None | $16 | 1 payment
|
| Amarin Pharma | Vascepa | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 94.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1912081654
- Licence
- CA G65848California G65848: Current · expires 2027-05-31
- Trained
- Northwestern University Feinberg Medical School, 1988 · 38 years ago
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00G658480
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 1500 Southgate Ave, Suite 202, Daly City, CA, 94015
- NPI first listed
- 2006-10-25
- NPI last updated
- 2007-07-12
This is when the NPI record was last certified, not a medical board exam.